Radiotherapy & Oncology
Volume 95, Issue 1 , Pages 3-22 , April 2010

Proton vs carbon ion beams in the definitive radiation treatment of cancer patients

  • Herman Suit

      Affiliations

    • Department of Radiation Oncology, Boston, MA, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
    • ,
  • Thomas DeLaney

      Affiliations

    • Department of Radiation Oncology, Boston, MA, USA
    • ,
  • Saveli Goldberg

      Affiliations

    • Department of Radiation Oncology, Boston, MA, USA
    • ,
  • Harald Paganetti

      Affiliations

    • Department of Radiation Oncology, Boston, MA, USA
    • ,
  • Ben Clasie

      Affiliations

    • Department of Radiation Oncology, Boston, MA, USA
    • ,
  • Leo Gerweck

      Affiliations

    • Department of Radiation Oncology, Boston, MA, USA
    • ,
  • Andrzej Niemierko

      Affiliations

    • Department of Radiation Oncology, Boston, MA, USA
    • ,
  • Eric Hall

      Affiliations

    • Center for Radiological Research, Columbia University, New York, NY, USA
    • ,
  • Jacob Flanz

      Affiliations

    • Department of Radiation Oncology, Boston, MA, USA
    • ,
  • Josh Hallman

      Affiliations

    • Department of Radiation Oncology, Boston, MA, USA
    • ,
  • Alexei Trofimov

      Affiliations

    • Department of Radiation Oncology, Boston, MA, USA

Received 9 September 2009 ,Revised 22 January 2010 ,Accepted 23 January 2010.

References 

  1. Delaney T, Kooy H. Proton and charged particle radiotherapy. Lippincott Williams & Wilkins: Philadelphia; 2008;
  2. Goitein M. Trials and tribulations in charged particle radiotherapy. Radiother Oncol. 2009;[Epub ahead of print]
  3. Jones B. Presidents conference paper. The case for particle therapy. Br J Radiol. 2006;79:24–31
  4. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clinical Oncol. 2007;25:953–964
  5. Turesson I, Johansson K, Mattisson S. The potential of proton and light ion beams in radiotherapy. Acta Oncol. 2003;42:107–114
  6. Weber U, Kraft G. Comparison of carbon ions versus protons. Cancer J. 2009;15:325–332
  7. Brada M, Pijls-Johannesma M, Dose Ruysscher D. Current clinical evidence for proton therapy. Cancer J. 2009;15:319–324
  8. Wilkens J, Oelfke U. Direct comparison of biologically optimized spread-out Bragg peaks for protons and carbon ions. Int J Rad Oncol Biol Phys. 2008;70:262–266
  9. Brown A, Suit H. The centenary of the discovery of the Bragg peak. Radiother Oncol. 2004;73:265–268
  10. Pshenichnov I, Mishustin I, Greiner W. Neutrons from fragmentation of light nuclei in tissue like media: a study with the GEANT4 toolkit. Phys Med Biol. 2005;50:5493–5507
  11. Lomax A, Bortfeld T, Goitein G, et al. A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy. Radiother Oncol. 1999;51:257–271
  12. Endo S, Takada M, Onizuka Y, et al. Microdosimetric evaluation of secondary particles in a phantom produced by carbon 290 MeV/nucleon ions at HIMAC. J Radiat Res. 2007;48:397–406
  13. Haettner E, Iwase H, Schardt D, et al. Experimental fragmentation studies with 12C therapy beams. Radiat Prot Dosimetry. 2006;122:485–487
  14. Blakely EA, Tobias CA, Tracy CH, et al. Inactivation of human kidney cells by high-energy mono-energetic heavy ion beams. Radiat Res. 1979;80:122–160
  15. Kanai T, Endo M, Minohara S, et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy ion radiation therapy. Int J Rad Oncol Biol Phys. 1999;44:201–210
  16. Wroe A, Clasie B, Kooy H, et al. Out-of field dose equivalents delivered by passively scattered therapeutic proton beams for clinically relevant field configurations. Int J Rad Oncol Biol Phys. 2009;71:306–313
  17. Safai S, Bortfeld T, Engelsman M. Comparison between the lateral penumbra of a collimated double-scattered beam and uncollimated scanning beam in proton radiotherapy. Phys Med Biol. 2008;53:1729–1750
  18. Lomax A, Pedroni E, Rutz H, Goitein G. The clinical potential of intensity modulated proton therapy. Z Med Phys. 2004;14:147–152
  19. Kramer M, Jakel O, Haberer T, et al. Treatment planning for scanned ion beams. Radiother Oncol. 2004;73:80–85
  20. Kempe J, Gudowska I, Brahme A. Depth absorbed dose and LET distributions of therapeutic 1H, 4He, 7Li, and 12C beams. Med Phys. 2007;34:183–192
  21. Wroe A, Rosenfeld A, Schulte R. Out-of-field dose equivalents delivered by proton therapy of prostate cancer. Med Phys. 2007;34:3449–3456Dosage error in article text. 2008; 35:3398
  22. Mesoloras G, Sandison G, Stewart R, et al. Neutron scattered dose equivalent to a fetus from proton radiotherapy of the mother. Med Phys. 2006;33:2479–2490
  23. Yonai S, Matsufuji N, Kanai T, et al. Measurement of neutron ambient dose equivalent in passive carbon-ion and proton radiotherapies. Med Phys. 2008;35:4782–4792
  24. Stovall M, Blackwell C, Cundiff J, et al. Fet al. dose from radiotherapy with proton beams: report of AAPM Radiation Therapy Committee Task Group No 36. Med Phys. 1995;22:63–82
  25. Schneider U, Agosteo S, Pedroni E, et al. Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys. 2002;53:244–251
  26. Tsujii H, Minohara S, Noda K. Heavy particle radiation therapy: system design and application. Reviews of Accelerator Science and Technology. 2009;2:93–110
  27. Goitein M. Compensation for inhomogeneities in charged particle radiotherapy using computed tomography. Int J Rad Oncol Biol Phys. 1978;4:499–508
  28. Urie M, Goitein M, Wagner M. Compensating for heterogeneities in proton radiation therapy. Phys Med Biol. 1984;29:553–566
  29. Weber U, Kraft G. Comparison of carbon ions vs protons. He Cancer J. 2009;15:325–332
  30. Prescribing, Recording, and Reporting Proton-Beam Therapy. Report 78, J Int Comm Radiat Units Meas 2007;7:2.
  31. Paganetti H, Niemierko A, Ancukiewicz M, et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 2002;53:407–421
  32. Gerweck L, Kozin S. Relative biological effectiveness of proton beams in clinical therapy. Radiother Oncol. 1999;50:135–142
  33. Warenius H, Britten RA, Peacock JH. The relative cellular radiosensitivity of 30 human in vitro cell lines of different histological type to high LET 62.5 MeV (p → Be+) fast neutrons and 4 MeV photons. Radiother Oncol. 1994;30:83–89
  34. Suzuki M, Kase Y, Yamaguchi H, et al. Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon ion beams. Int J Rad Oncol Biol Phys. 2000;48:241–250
  35. Ando K, Kase Y. Biological characteristics of carbon-ion therapy. Int J Radiati Biol. 2009;85:715–728
  36. Weyrather W, Ritter S, Scholz M, et al. RBE for carbon track-segmented irradiation in cell lines of differing repair capacity. Int J Radiat Biol. 1999;75:1357–1364
  37. Furusawa Y, Fukutsu K, Itsukaichi H, et al. Inactivation of aerobic and hypoxic cells from three different cell lines by accelerated 3HE-, 12C-, and 20Ne-ion beams. Radiat Res. 2000;154:485–496
  38. Karger C, Peschke P, Sanchez-Brandelik R, et al. Radiation tolerance of the rat spinal cord after 6 and 18 fractions of photons and carbon ions: experimental results and clinical implications. Int J Rad Oncol Biol Phys. 2006;66:1488–1497
  39. Robbins M, Barnes D, Campling D, et al. The relative biological effectiveness of fractionated doses of fast neutrons (42 MeVd––Be), for normal tissues in the pig. IV. Effects on renal function. Br J Radiol. 1991;64:823–830
  40. Hall E, Giacci A. Radiobiology for the radiologist. Sixth edition. Lippincott Williams and Wilkins: Philadelphia PA; 2006;
  41. Becker A, Hänsgen G, Bloching M, et al. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys. 1998;42:35–41
  42. Brizel D, Dodge R, Clough R, et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53:113–117
  43. Nordsmark M, Bentzen S, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77:18–24
  44. Parker C, Milosevic M, Toi A, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:750–757
  45. Blakely E. Biology of bevalac beam: cellular studies. In:  Skarsgard L editors. Pion and heavy ion radiation therapy: pre-clinical and clinical studies. Amsterdam: Elsevier; 1982;p. 229–250
  46. Raju M. Heavy particle radiotherapy. Academic Press, Inc.: New York, NY; 1980.
  47. Miller R, Marino S, Martin S, et al. Neutron-energy dependent cell survival and oncogenic transformation. J Radiat Res. 1999;40:53–59
  48. Han Z, Suzuki H, Suzuki F, et al. Relative biological effectiveness of accelerated heavy ions for induction of morphological transformation in Syrian hamster embryo cells. J Radiat Res. 1998;39:193–201
  49. Bettega D, Calzolari P, Hessel P, et al. Neoplastic transformation induced by carbon ions. Int J Radiat Oncol Biol Phys. 2009;3:861–868
  50. Stone R. Neutron therapy and specific ionization. Janeway Memorial Lecture. Am J Roentgenol Radium Ther. 1948;59:771–785
  51. Catterall M, Bewley D, Sutherland I. Second report of a randomized clinical trial of fast neutrons compared with chi or gamma rays in treatment of advanced tumours of head and neck. Br Med J. 1977;1:1642
  52. Stafford N, Waldron J, Davies D, et al. Complications following fast neutron therapy for head and neck cancer. J Laryngol Otol. 1992;106:144–146
  53. Blake P, Catterall M, Eddington R. Treatment of malignant melanoma by fast neutrons. Br J Surg. 1985;72:517–519
  54. MacDougall R, Orr J, Kerr G, et al. Fast neutron treatment for squamous cell carcinoma of the head and neck: final report of Edinburgh randomized trial. Br Med J. 1990;301:1241–1242
  55. Maor M, Errington D, Caplan R, et al. Fast-neutron therapy in advanced head and neck cancer. Int J Rad Oncol Biol Phys. 1995;32:599–604
  56. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25:4066–4074
  57. Lindsely K, CHO P, Stelzer K. Clinical trials of neutron therapy in the United States. Bull Cancer/Radiother. 1996;83:78s–86s
  58. Laramore G, Krall J, Griffin T, et al. Neutron versus photon for unresectable salivary gland tumors: final report of an RTOG-MRC randomized trial. Int J Rad Oncol Biol Phys. 1993;27:235–240
  59. Griffin B, Laramore G, Russell K, et al. Fast neutron radiation therapy for advanced malignant salivary gland tumors. Radiother Oncol. 1988;12:105–111
  60. Wang C, Goodman M. Photon irradiation on unresectable carcinomas of salivary glands. Int J Rad Oncol Biol Phys. 1991;21:567–569
  61. Wijffels K, Hoogsteen I, Lok J, et al. No detectable hypoxia in malignant salivary gland tumors: preliminary results. Int J Rad Oncol Biol Phys. 2009;73:1319–1325
  62. Laramore G, Griffin T. Fast neutron radiotherapy: where have we been and where are we going? Jury is still out-regarding Maor et al.. Int J Rad Oncol Biol Phys. 1995;32:879–882
  63. Duncan W. An evaluation of the results of neutron therapy trials. Acta Oncol. 1994;33:299–306
  64. Wagner F, Kneschaurek P, Kastenmüller A, et al. The Munich fission neutron therapy facility MEDAPP at the research reactor FRM II. Strahlenther Onkol. 2008;184:643–646
  65. Fowler J. The linear quadratic formula and progress in fractionated radiation therapy. Br J Radiol. 1989;62:679–692
  66. Fowler J. Sensitivity analysis of paramentes in linear quadratic radiobiologic modeling. Int J Radiat Oncol Biol Phys. 2009;73:1532–1537
  67. Stuschke M, Pottgen C. Altered fractionation schemes in radiotherapy. Front Radiat Ther Oncol. 2010;42:150–156
  68. Iwata H, Shibamoto Y, Murata R, et al. Estimation of errors associated with use of linear-quadratic formalism for evaluation of biologic equivalence between single and hypofractionated radiation doses: an in vitro study. Int J Radiat Oncol Biol Phys. 2009;75:482–488
  69. Joiner M, van der Kogel B. Basic clinical radiobiology. Fourth edition. London: Hodder-Arnold Publishing; 2009;
  70. Kirkpatrick J, Meyer J, Marks L. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 2008;18:240–243
  71. Brenner D. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol. 2008;18:234–239
  72. Gunderson L, Tepper, editors. Clinical radiation oncology. New York: Churchill Livingstone; 2000.
  73. Halperin E, Perez C, Brady L, editors. Principles and practice of radiation oncology. Philadelphia: Lippincott Williams and Wilkins; 2008, p. 2–75.
  74. Peckham M et al., editors. Oxford textbook of oncology. Oxford Medical Publications; 1995.
  75. Henderson F, McCool K, Seigle J, et al. Treatment of chordomas with CyberKnife: Georgetown University experience and treatment recommendations. Neurosurgery. 2009;64:A44–A53
  76. Bentzen S, Ritter M. The α/β ratio for prostate cancer: What is it, really?. Radiother Oncol. 2005;76:1–3
  77. Williams S, Taylor J, Liu N, Tra Y, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:24–33
  78. Koukourakis M, Skarlatos J, Kosma L, et al. Radiotherapy alone for non-small cell lung carcinoma. Five-year disease-free survival and patterns of failure. Acta Oncol. 1995;34:525–530
  79. Zeman E. Biological basis of radiation oncology. In:  Gunderson L,  Tepper J editor. Clinical radiation oncology. New York: Churchill Livingstone; 2000;p. 1–41
  80. Tai A, Erickson B, Khater K, et al. Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation. Int J Radiat Oncol Biol Phys. 2008;70:900–907
  81. Toya R, Murakami R, Yasunaga T, et al. Radiation therapy for lymph node metastases from hepatocellular carcinoma. Hepatogastroenterology. 2009;56:476–480
  82. Terahara A, Niemierko A, Goitein M, et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys. 1999;45:351–358
  83. Noël G, Feuvret L, Calugaru V. Et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol. 2005;44:700–708
  84. Noël G, Feuvret L, Ferrand R, et al. Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas. Neurosurg. 2004;55:1252–1261
  85. Hug E, Loredo L, Slater J, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg. 1999;432–439
  86. Ares C, Hug E, Lomax A, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Rad Oncol Biol Phys. 2009;75:1111–1118
  87. Debus J, Schulz-Eernter D, Schad L, et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int J Rad Oncol Biol Phys. 2000;47:591–596
  88. Hasegawa A, Mizoe J, Takagi R, et al. Carbon ion radiotherapy for skull base and paracervical tumors. In: Proceedings of NIRS MD Anderson symposium on clinical issues for particle therapy; 2008. p. 84–9.
  89. Schulz-Ertner D, Karger C, Feuerhake A, et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Rad Oncol Biol Phys. 2007;68:449–457
  90. Miyawaki D, Murakami M, Demizu Y, et al. Brain injury after proton therapy or carbon ion therapy for head-neck cancer and skull base tumors. Int Nat J Radiat Oncol Biol Phys. 2009;75:478–484
  91. Martin J, Niranjan A, Kondziolka D, et al. Radiosurgery for chordomas and chondrosarcomas of the skull base. J Neurosurg. 2007;107:758–764
  92. Rosenberg A, Nielsen G, Keel S, et al. Chondrosarcoma of the base of the skull: a clinicopathological study of 200 cases with emphasis on it’s distinction from chordoma. Am J Surg Path. 1999;23:1370–1378
  93. Schulz-Ertner D, Nikoghosyan A, Holger H, et al. Carbon ion radiotherapy of skull base chondrosarcomas. Int J Rad Oncol Biol Phys. 2007;67:171–177
  94. Imai R, Kamada T, Tsuji H, et al. Carbon ion radiotherapy for unresectable sacral chordomas. Cl Cancer Res. 2004;10:5741–5746
  95. Delaney T, Liebsch N, Pedlow F, Adams J, et al. Phase II study of high-dose photon/proton radiation therapy in the management of spine sarcomas. Int J Radiol Biol Phys. 2009;74:732–739
  96. Rutz H, Weber D, Sugahara S, et al. Extracranial chordoma: outcome in patients treated with function-preserving surgery followed by spot-scanning proton beam irradiation. Int J Radiat Oncol Biol Phys. 2007;67:512–520
  97. Gragoudas E, Wenjun LI, Goitein M, et al. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Opthalmol. 2002;120:1665–1671
  98. Gragoudas E. Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld lecture. IVOS. 2006;47:4666–4673
  99. Egger E, Schalenbourg A, Zografos L, et al. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Rad Oncol Biol Phys. 2001;51:138–147
  100. Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Rad Oncol Biol Phys. 2003;55:867–880
  101. Dendale R, Rouic L, Noel G, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institute-Orsay Proton Therapy Center. Int J Rad Oncol Biol Phys. 2006;65:780–787
  102. Tsuji H, Ishikawa H, Yanagi T, et al. Carbon-ion radiotherapy for locally advanced or unfavorably located choroidal melanoma: a phase I/II dose-escalation study. Int J Rad Oncol Biol Phys. 2007;67:857–862
  103. Dieckmann K, Georg D, Bogner J, Zehetmayer M, et al. Optimizing Linac-based stereotactic radiotherapy of uveal melanomas: 7 years’ clinical experience. Int J Rad Oncol Biol Phys. 2006;S47–S52
  104. Slater J, Yonemoto L, Mantik D, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Rad Oncol Biol Phys. 2005;62:494–500
  105. Mizoe J, Hasegawa A, Takagi R, et al. Carbon ion radiotherapy for head and neck tumors. In: Proceedings of NIRS MD Anderson symposium on clinical issues for particle therapy; 2008. p. 9–15.
  106. Pommier P, Liebsch N, Deschler D, et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132:1242–1249
  107. Schulz-Ertner D, Nikoghosyan A, Didinger B, et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer. 2005;104:338–344
  108. Schulz-Ertner D, Nikoghosyan A, Jäekel O. Feasibility and toxicity of combined photon and carbon ion radiotherapy for locally advanced adenoid cystic carcinomas. Int J Rad Oncol Biol Phys. 2003;56:309–604
  109. Mizoe J, Tsujii H, Kamada T, et al. Dose escalation study of carbon ion radiotherapy for locally advanced head and neck cancer. Int J Rad Oncol Biol Phys. 2004;60:358–364
  110. Douglas J, Lee S, Laramore G, et al. Neutron Radiotherapy for the treatment of locally advanced major salivary gland tumors. Head Neck. 1999;21:255–263
  111. Yanagi T, Mizoe J, Hasegawa A, et al. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Rad Oncol Biol Phys. 2009;74:15–20
  112. Bush D, Slater J, Shin B, et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004;126:1198–1203
  113. Nihei K, Ogino T, Ishikura S, et al. High dose proton beam therapy for Stage I non-small cell lung cancer. Int J Rad Oncol Biol Phys. 2006;65:107–111
  114. Hata M, Tokuuye K, Kagel K, et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Rad Oncol Biol Phys. 2007;68:786–793
  115. Miyamoto T, Baba M, Yamamoto N, et al. Curative treatment of stage I non-small cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Rad Oncol Biol Phys. 2007;67:750–758
  116. Fakiris A, Henderson MA, Witt TC, et al. Gamma-knife based Stereotactic radiosurgery for uveal melanoma. Stereotact Funct Neurosurg. 2007;85:106–112
  117. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a Phase II study of Stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4837
  118. Ng A, Tung S. Wong V Hypofractionated stereotactic radiotherapy for medically inoperable stage I non-small cell lung cancer–report on clinical outcome and dose to critical organs. Radiother Oncol. 2008;87:24–28
  119. Hoyer M, Roed H, Hansen A, et al. Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer. Int J Rad Oncol Biol Phys. 2006;66:S128–S135
  120. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2008;85:429–434
  121. Forquer J, Fakiris A, Timmerman R, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009;May 17 [E Pub ahead of print].
  122. Pettersson N, Nyman J, Johansson K. Radiation induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: A dose and volume response analysis. Radiother Oncol. 2009;91:360–368
  123. Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74:831–836
  124. Chiba T, Tokuuye K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005;11:3799–3805
  125. Kato H, Yassda S, Yamada S, et al. Carbon ion radiotherapy for hepatocellular carcinoma [HCC, hepatoma]. In: Proceedings of NRS MD Anderson symposium on clinical issues for particle therapy; 2008. p. 16–23.
  126. Mornex F, Girard N, Beziat C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies—mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys. 2006;66:1152–1158
  127. Shipley W, Verhey L, Munzenrider J, et al. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Rad Oncol Biol Phys. 1995;31:3–12
  128. Slater J, Rossi C, Yonemoto L, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Rad Oncol Biol Phys. 2004;59:348–352
  129. Zietmann A, De Silvio M, Slater J, et al. Comparison of conventional dose vs high dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA. 2005;294:1233–1239
  130. Tsuji H, Kato H, Yanhai T, et al. Carbon ion therapy for prostate cancer. In: Proceedings of NIRS MD anderson symposium on clinical issues for particle therapy; 2008. p. 62–71.
  131. Zelefsky M, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–1419
  132. Zelefsky M, Yamada Y, Cohen G, et al. Five year outcome of intra-operative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Rad Oncol Biol Phys. 2007;67:65–70
  133. Nomiya T, Tsuji H, Hirasawa N, et al. Carbon ion radiation therapy for primary renal cell carcinoma: initial clinical experience. Int J Rad Oncol Biol Phys. 2008;72:828–833
  134. Preston D, Shimizu Y, Pierce D, et al. Studies of mortality of atomic bomb survivors. Report 13: solid cancer and non-cancer disease mortality: 1950–1997. Radiat Res. 2003;160:381–407
  135. Suit H, Goldberg S, Niemierko A, et al. Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res. 2007;167:12–42Erratum in: Radiat Res 2007;167:748
  136. Chao K, Blanco A, Dempsey J. A conceptual model integrating spatial information to assess target volume coverage for IMRT treatment planning. Int J Rad Oncol Biol Phys. 2003;56:1438–1449

PII: S0167-8140(10)00067-8

doi: 10.1016/j.radonc.2010.01.015

Radiotherapy & Oncology
Volume 95, Issue 1 , Pages 3-22 , April 2010

Article Tools

* Image Usage & Resolution